Anti-PSMP Antibodies for Blocking Organ Fibrosis Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrotic diseases such as liver fibrosis, nonalcoholic fatty liver disease, alcoholic liver disease, primary sclerosing cholangitis, primary biliary cholangitis, lung fibrosis, graft-versus-host disease, acute kidney injury, and chronic kidney disease lack effective therapeutic options, particularly for advanced stages or conditions with significant morbidity and mortality.
Innovation Solution
Administration of a PC3-secreted microprotein (PSMP) antagonist, specifically a neutralizing anti-PSMP antibody, to target and reduce the receptor-mediated activity of PSMP, thereby inhibiting fibrosis progression in various organs including the liver, lung, and kidneys.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSMP antagonist is administered to treat fibrotic diseases, then fibrosis progression is inhibited and therapeutic benefit is achieved, but no approved drugs currently exist for moderate to advanced fibrosis stages
Solution Approach 1:
The patent uses PSMP (prostate secreted microprotein) as a mediator to target and inhibit fibrotic processes. The PSMP antagonist acts as an intermediary that blocks the interaction between PSMP and its receptors, thereby preventing fibrosis progression in liver, lung, and kidney diseases where no approved therapies currently exist for advanced stages.
2Ease of operation
If current treatments are used for fibrotic diseases, then some symptomatic relief may be achieved, but effective therapeutic options are lacking particularly for advanced stages with significant morbidity and mortality
Solution Approach 1:
The PSMP antagonist employs preliminary anti-action by blocking the fibrotic pathway before extensive tissue damage occurs. By inhibiting PSMP-mediated fibrogenesis early in the disease process, the treatment prevents progression to advanced stages with high morbidity and mortality, thereby improving both accessibility and effectiveness of therapy.
3Duration of action of stationary object
If fibrosis progresses in liver, lung or kidney, then organ function is maintained initially, but excessive ECM accumulation leads to disruption of organ architecture and loss of function
Solution Approach 1:
The patent converts the harmful fibrotic process into a beneficial therapeutic outcome by using PSMP antagonist to block the pathological ECM accumulation. The treatment transforms the understanding of fibrosis from an irreversible damaging process to a targetable pathway, where inhibiting PSMP activity prevents the harmful effects while preserving organ function and architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PSMP antagonist effectively reduces fibrosis and associated complications by inhibiting the chemotactic activity of PSMP, offering therapeutic benefits for fibrotic diseases across multiple organ systems, including liver cirrhosis, lung fibrosis, and kidney diseases.
Implementation Method 1
Administration of a PC3-secreted microprotein (PSMP) antagonist, specifically a neutralizing anti-PSMP antibody, to target and reduce the receptor-mediated activity of PSMP
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3C
AI summary
Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies.